bit.bio

United States - Cambridge, Cambridgeshire

• 05/11/2021
• Series B
• $103,000,000

bit.bio is an award-winning human synthetic biology enterprise. Our mission is coding cells for health. To do so, we apply the principles of computation to biology.

Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies.

To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy.

Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.

Related People

Mark KotterFounder

United States - Greater Cambridge Area

Neurosurgeon, stem cell biologist, and serial entrepreneur.

Dedicated to transitioning biology to engineering in to address the most important human needs, including cancer and the consequences of poor health due to ageing.

Founder of synthetic cell company bit.bio, and co-founder of cultured meat startup Meatable and Myelopathy.org, a charity dedicated to common form of spinal cord injury.

LinkedIn https://www.linkedin.com/in/mark-kotter-3505872a/